InGell Labs operates from state-of-the-art R&D facilities operated by InnoCore Pharmaceuticals for formulation development and quality-assured synthesis and manufacturing of polymers.
Formulation development is currently performed up to the level of supplying formulations for animal trials and biocompatibility/tox studies.
The InGell-polymers are custom engineered for effective formulation development. Once selected, they are scaled-up towards the appropriate level by our partner PolyVation, where they can be manufactured according to cGMP-standards.
Together with our partner InnoCore Pharmaceuticals we house new state-of-the-art labs and offices with access to class B/C clean room facilities enabling us to supply formulations for clinical uses.
All analytical facilities needed to characterize the polymers and formulations are on board ranging from HPLC/UPLC, GPC/SEC, NMR to rheology, ELISA and more.
Our analytical practices are performed under the operational quality guidelines of InnoCore Pharamaceuticals, who is certified by KEMA for cGMP-analytical standards.